Side-effects of checkpoint inhibitor-based combination therapy

Current Opinion in Oncology

Volumn 28, Issue 4, 2016, Pages 306-313

  Kourie, Hampig R ^a   Klastersky, Jean A ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

anti cytotoxic T lymphocyte associated protein 4; anti programmed cell death protein 1; anti programmed cell death protein ligand 1; chemotherapy; targeted molecular therapy and immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; CARBOPLATIN; CELL ANTIBODY; CHECKPOINT INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGIC AGENT; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PAZOPANIB; PEMBROLIZUMAB; PEMETREXED; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; SUNITINIB; TALIMOGENE LAHERPAREPVEC; TICILIMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHILL; COLITIS; COUGHING; DESQUAMATION; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; ENTEROCOLITIS; FATIGUE; FEVER; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOPHYSITIS; HYPOTHYROIDISM; LIVER TOXICITY; LOSS OF APPETITE; MACULOPAPULAR RASH; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MYASTHENIA GRAVIS; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA; VITILIGO; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CTLA-4 ANTIGEN; HUMANS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84964734906     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000295     Document Type: Review

References (23)

1. Kim T, Amaria RN, Spencer C, et al. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 2014; 11:237-246.
2. Hu-Lieskovan S, Robert L, Homet Moreno B, et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 2014; 32:2248-2254.
3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34.
4. Kourie HR, Klastersky J. Immune checkpoint inhibitors side effects and management: what we need to know. Immunotherapy 2016.
5. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
6. Weber J, Hamid O, Amin A, et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun 2013; 13:7.
7. Antonio S, Brahmer G, Gettinger S, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol 2014; 32 (5s). (suppl; abstr 8113).
8. Liu S, Powderly J, Camidge DR, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol, 2015 ASCO Annual Meeting, Vol 33, No 15-suppl (May 20 Supplement) 2015; 8030.
9. Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-1366.
10. Puzanov I, Milhem M, Andtbacka R, et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts, Vol 32, No 15-suppl (May 20 Supplement) 2014; 9029.
11. Hodi S, Lee S, McDermott D, et al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. J Clin Oncol, 2013 ASCO Annual Meeting Abstracts, Vol 31, No 18-suppl (June 20 Supplement) 2013; CRA9007.
12. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-2017.
13. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-133.
14. Hammers H, Plimack E, Infante J, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2014; 32 (5s). (suppl; abstr 4504).
15. Antonio S, Gettinger S, Quan Man Chow L, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. J Clin Oncol 2014; 32 (5s). (suppl; abstr 8023).
16. Antonia S, Bendell J, Taylor M, et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol 2015; 33:. (suppl; abstr 7503).
17. Puzanov I, Callahan M, Linette G, et al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J Clin Oncol, 2014 ASCO Annual Meeting Abstracts, Vol 32, No 15-suppl (May 20 Supplement) 2014; 2511.
18. Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2:632-642.
19. Rini BI, Stein M, Shannon P, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011; 117:758-767.
20. Amin A, Plimack E, Infante J, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 2014; 5010. Vol 32, No 15-suppl (May 20 Supplement).
21. Khoja L, Butler MO, Chappell MA, et al. Increased treatment-related toxicity subsequent to an anti-PD-1 agent. Curr Oncol 2015; 22:e320-e322.
22. Hodi F, Gibney G, Sullivan R, et al. An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). ECC; 2015; Abstract 23 LBA.
23. Klatersky J. Adverse events of targeted therapies. Curr Opin Oncol 2014; 26:395-402.